Concepedia

Xiaoni Liu

XL

10

Publications

705

Citations

10

H-Index

2011

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Peking University Third Hospital

Fudan University

Bristol-Myers Squibb (Sweden)

Xiaoni Liu is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

2011–2022

10

Publications

10

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula et al. · Diabetes Care · 2013 · 281 citations · Full text

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Sreeneeranj Kasichayanula, Xiaoni Liu, Melanie Pe Benito et al. · British Journal of Clinical Pharmacology · 2012 · 117 citations · Full text

Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study

Sreeneeranj Kasichayanula, Xiaoni Liu, Weijiang Zhang et al. · Clinical Therapeutics · 2011 · 88 citations

, , +9

Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin

Sreeneeranj Kasichayanula, Ming Chang, Xiaoni Liu et al. · Advances in Therapy · 2012 · 60 citations · Full text

, , +6

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects

Rong Shi, Marek Honczarenko, Sean X. Zhang et al. · The Journal of Clinical Pharmacology · 2016 · 43 citations · Full text

, , +20

Rows per page

1–5 of 10